Follistatin 344 — Research Overview
Chemical Name: Follistatin isoform FS344 (alternatively spliced cDNA encoding the FS315 circulating protein after signal peptide cleavage) Also Known As: FS344, Follistatin-344, FS315 (the mature circulating protein produced from FS344 transcript) Structure: 344-amino acid glycoprotein precursor; after post-translational removal of the 29-amino acid signal peptide the mature circulating isoform is 315 amino acids (FS315). Molecular weight approximately 37 kDa as core protein, higher as glycosylated form. Origin: Endogenous human protein; alternatively spliced variant of the follistatin gene (chromosome 5q11.2, six exons). First isolated from ovarian follicular fluid in the late 1980s as a follicle-stimulating hormone-suppressing factor. Category: Endogenous glycoprotein / myostatin and activin antagonist / TGF-beta superfamily inhibitor / muscle disease gene therapy research target
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Follistatin 344?
Follistatin is an endogenous secreted glycoprotein that functions as a potent antagonist of multiple members of the TGF-beta superfamily, most notably myostatin (GDF-8) and the activins. It was originally identified as a protein capable of suppressing follicle-stimulating hormone (FSH) secretion from the pituitary — a property that initially raised concerns about reproductive off-target effects when follistatin was considered for therapeutic applications targeting skeletal muscle.
The follistatin gene generates two major isoforms through alternative splicing. The full-length FS344 transcript encodes a 344-amino acid precursor that, after removal of the 29-amino acid signal peptide, produces the FS315 circulating isoform. A shorter FS317 transcript lacking exon 6 produces FS288, the membrane-bound short isoform. This distinction is critical for research applications: FS288 has high affinity for heparan sulfate proteoglycans, localizes preferentially to gonadal tissue and follicular fluid, potently suppresses FSH, and has the highest affinity for pituitary activins — producing significant off-target endocrine effects. FS315 (produced from the FS344 transcript) has approximately 10-fold lower affinity for activin than FS288, is primarily serum-based rather than membrane-bound, and has substantially reduced affinity for the hypothalamic-pituitary-gonadal axis.
This isoform distinction is the reason that research programs targeting skeletal muscle specifically use FS344 as the gene construct. By delivering the FS344 transcript, researchers produce the FS315 circulating protein — achieving potent myostatin inhibition in skeletal muscle with a substantially improved safety profile relative to the full activin-suppressing activity of FS288.
Follistatin 344 is classified as a WADA prohibited substance under the category of gene doping and peptide hormones, growth factors, and related substances (S2/S4). It is not approved by the FDA for any indication.
The Myostatin Pathway — Scientific Context
Myostatin (GDF-8, growth differentiation factor 8) is a TGF-beta superfamily member produced in skeletal muscle cells that functions as a primary negative regulator of muscle mass. It was identified in 1997 by McPherron, Lawler, and Lee as the gene responsible for the dramatically increased muscle mass seen in cattle with natural loss-of-function mutations — a phenotype that had been documented for centuries in “double-muscled” breeds such as Belgian Blues and Piedmontese.
Myostatin is activated through a stepwise proteolytic process and, once active, binds to activin type IIB (ActRIIB) receptors, triggering a downstream signaling cascade through ALK4/ALK5 type I receptors and SMAD2/3 phosphorylation. The SMAD complex enters the nucleus and activates gene transcription that suppresses muscle protein synthesis and myoblast proliferation. Myostatin therefore functions as a molecular brake on skeletal muscle hypertrophy — a brake whose removal or inhibition produces dramatic increases in muscle mass.
Several endogenous proteins bind and sequester myostatin in an inactive state in circulation: follistatin, follistatin-related gene (FLRG), and growth differentiation factor-associated serum protein-1 (GASP-1). Among these, follistatin is the most potent and has the broadest inhibitory activity — it does not bind solely myostatin but also inhibits activins (particularly activin A and activin B) and certain bone morphogenetic proteins including BMP-2, BMP-4, BMP-7, and BMP-15. This broad TGF-beta superfamily antagonism means follistatin’s effects on muscle mass reflect simultaneous inhibition of multiple growth-limiting signaling pathways, which may explain why its effects on muscle hypertrophy in preclinical models appear to exceed those of selective myostatin blockade alone.
Mechanism of Action
Follistatin 344 produces FS315 which binds directly to myostatin and activins with high affinity, forming stable non-covalent complexes that prevent these ligands from engaging their cell surface receptors. The result is blockade of ActRIIB binding and suppression of downstream SMAD2/3 signaling that would otherwise inhibit muscle protein synthesis and myoblast proliferation.
The consequences of this inhibitory pathway suppression include release of the brake on satellite cell activation — myosatellite cells are muscle-resident stem cells responsible for muscle repair and hypertrophic growth. Published research has demonstrated that follistatin-induced muscle hypertrophy depends in part on satellite cell proliferation, with irradiated muscle (lacking functional satellite cells) showing a reduced but still meaningful hypertrophic response, confirming dual mechanisms of myofiber hypertrophy and satellite cell-mediated growth.
Follistatin also interacts with the actin cytoskeleton organization and integrin signaling pathways within muscle fibers, with changes in fiber architecture accompanying the increase in fiber cross-sectional area. Muscle hypertrophy induced by follistatin has been documented to affect both the injected limb muscles at the local level and remote muscles through the secreted FS315 protein entering the circulation from the injection site — enabling systemic muscle effects from local gene delivery.
An important mechanistic note: because follistatin inhibits activins as well as myostatin, its effects on muscle are more complex than those of selective myostatin-only antagonists. Published research comparing follistatin to FLRG and GASP-1 in controlled animal studies found that FS344 consistently produced the greatest increases in muscle mass and strength of any myostatin inhibitor tested — an advantage attributed to its combined inhibition of multiple TGF-beta superfamily members rather than myostatin alone.
Published Research
Study 1 — Foundational: Long-Term Muscle Mass and Strength Enhancement by Single Gene Administration
Authors: Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A et al. (Nationwide Children’s Hospital, Ohio State University) Year: 2008 Journal: Proceedings of the National Academy of Sciences USA PMID: 18362333 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC2393740/
This landmark study established the long-term efficacy and safety profile of AAV1-delivered FS344 in both normal and dystrophic mice, directly comparing three myostatin inhibitor constructs: FS344, FLRG, and GASP-1.
All three myostatin inhibitor transgenes produced increased muscle mass and strength following a single intramuscular AAV1 injection; however FS344 produced the greatest increases in muscle size and function and was well tolerated for greater than two years of follow-up with no adverse effects on cardiac pathology or reproductive capacity in either male or female animals.
In dystrophic mdx mice (the standard model of Duchenne muscular dystrophy) a single injection of AAV1.FS344 reversed muscle pathology and improved strength even when administered in 6.5-month-old animals showing advanced cycles of muscle degeneration and regeneration.
A 15-fold increase in serum follistatin was seen at high dose (1.5 x 10 to the 12 vg/kg) and a 6-fold increase at low dose (1.5 x 10 to the 11 vg/kg), confirming that the FS315 protein produced from the FS344 transgene entered the circulation and produced systemic muscle effects remote from the injection site.
Hindlimb grip strength improved across greater than 2 years in all treated mice, with the greatest differences in AAV1-FS344 treated animals compared to GFP controls.
The authors concluded that FS344 may offer a more powerful strategy than constructs targeting solely myostatin, because of additive effects resulting from follistatin’s involvement in multiple TGF-beta signaling pathways.
Study 2 — Nonhuman Primate Safety and Efficacy: Critical Bridge to Human Research
Authors: Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A et al. (Nationwide Children’s Hospital) Year: 2009 Journal: Science Translational Medicine Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC2852878/
This nonhuman primate study represented the essential pre-clinical step before human clinical trials, testing AAV1-FS344 in cynomolgus macaque monkeys — the closest available model to human physiology before proceeding to human trials.
When injected into the quadriceps of macaque monkeys, AAV1-FS344 induced pronounced and durable increases in muscle size and strength.
The FS344 transgene exhibited long-term expression for up to 15 months after a single gene transfer. Muscle growth was apparent in both MCK-FS and CMV-FS promoter groups for the first 12 weeks after treatment, after which growth rates stabilized — suggesting a feedback mechanism that sustains enlarged muscle fibers while preventing uncontrolled growth, consistent with the physiology of natural myostatin inhibition.
Long-term expression of the transgene did not produce any abnormal changes in the morphology or function of key organs, indicating safety of gene transfer over extended observation.
The CMV promoter produced the largest effect on muscle size, identifying promoter selection as an important variable for optimizing therapeutic dose.
The authors noted the important caveat that these animals did not have degenerative muscle disease, and that the findings in healthy primates may not directly translate to clinically effective outcomes in patients with genetic muscle disorders characterized by cycles of degeneration and regeneration.
Study 3 — Phase 1/2a Human Clinical Trial: Becker Muscular Dystrophy
Authors: Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP et al. (Nationwide Children’s Hospital, Ohio State University) Year: 2015 Journal: Molecular Therapy PMID: 25322757 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4426808/
This proof-of-principle Phase 1/2a trial was the first human clinical study of FS344 gene therapy, delivering AAV1.CMV.FS344 by direct bilateral intramuscular quadriceps injection in six patients with Becker muscular dystrophy — the first published human data for follistatin gene therapy.
Cohort 1 enrolled three subjects receiving 3 x 10 to the 11 vg/kg per leg at the lower dose. Patients 01 and 02 improved their 6-minute walk test (6MWT) distance by 58 meters and 125 meters respectively compared to baseline over one year of follow-up. Patient 03 showed no change.
Cohort 2 enrolled three subjects receiving 6 x 10 to the 11 vg/kg per leg at the higher dose. Patients 05 and 06 improved 6MWT by 108 meters and 29 meters respectively. Patient 04 showed no improvement.
No adverse effects were encountered across either cohort.
Histological examination of post-treatment muscle biopsies corroborated clinical benefit, showing reduced endomysial fibrosis, reduced central nucleation, a more normal fiber size distribution, and muscle hypertrophy — especially at the high dose. At high dose, fibrosis was reduced to 35% of baseline for Patient 05 and 43% of baseline for Patient 06 (P equal to 0.017).
The authors concluded that the safety findings in combination with gene expression in muscle and functional improvement provide a firm foundation for application of AAV1.FS344 gene delivery for other muscle diseases, and announced initiation of a trial in sporadic inclusion body myositis.
Study 4 — Human Clinical Trial Extension: Sporadic Inclusion Body Myositis
Authors: Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP et al. (Nationwide Children’s Hospital) Year: 2017 Journal: Molecular Therapy Full text: https://www.sciencedirect.com/science/article/pii/S1525001617300928
This study extended the FS344 clinical program to sporadic inclusion body myositis (sIBM), the most common acquired muscle disorder in adults over 50, characterized by progressive quadriceps weakness and an inflammatory infiltration that responds poorly to immunosuppressive therapies. Six sIBM subjects received rAAV1.CMV.huFS344 at 6 x 10 to the 11 vg/kg bilaterally into the quadriceps.
The primary outcome — 6-minute walk test distance — showed an annualized median improvement of plus 56 meters per year for treated subjects compared to a decline of minus 25.8 meters per year in eight untreated matched subjects (P equal to 0.01).
Four of the six treated subjects showed 6MWT improvements ranging from 58 to 153 meters. Two were minimally improved at 5 to 23 meters.
Treatment effects included decreased fibrosis and improved muscle regeneration on histological analysis.
An important limitation note: This trial received a published critique in the same journal (Molecular Therapy, 2017) raising significant methodological concerns. Specifically, the study was an open-label, single-group Phase 1A trial with no comparator or control group as registered. The treated subjects received at minimum four potentially therapeutic interventions simultaneously — follistatin gene therapy, high-dose prednisone for approximately 60 days, a prescribed and monitored exercise program, and the known effects of open-label investigational treatment participation. Critics argued that attributing functional outcomes specifically to follistatin gene therapy was not possible given the study design, and noted that the reported primary outcome measure differed from the ClinicalTrials.gov-registered primary outcome. This methodological critique has not been formally resolved in the published literature and remains an important caveat for interpreting the sIBM functional outcome data specifically.
Study 5 — Satellite Cell and Activin Mechanism: Follistatin-Induced Hypertrophy Pathways
Authors: Barbarite E, Shibaguchi T et al. Year: 2010 Journal: American Journal of Physiology — Endocrinology and Metabolism Full text: https://journals.physiology.org/doi/full/10.1152/ajpendo.00193.2009
This mechanistic study investigated the cellular basis of follistatin-induced muscle hypertrophy by comparing follistatin overexpression in normal and irradiated muscle (irradiation eliminates satellite cell proliferative capacity) and in myostatin knockout mice.
Follistatin overexpression increased muscle weight by approximately 37% in control animals but only 20% in irradiated muscle, confirming that satellite cell proliferation contributes meaningfully to follistatin-induced hypertrophy though it is not the sole mechanism.
Muscle hypertrophy caused by follistatin reached the same magnitude in myostatin knockout mice as in wild-type mice, providing direct experimental evidence that myostatin is not the only TGF-beta superfamily ligand regulated by follistatin that contributes to the regulation of muscle mass — confirming the activin pathway as a significant additional target.
Using a follistatin mutant (FSI-I) that does not bind activin with high affinity, the researchers demonstrated that activin binding contributes substantially to follistatin-induced hypertrophy, independent of myostatin inhibition alone.
These findings established that follistatin’s hypertrophic effects on skeletal muscle are mediated by combined inhibition of both myostatin and activin signaling, explaining why follistatin consistently outperforms selective myostatin-only inhibitors in comparative animal studies.
An Important Note on Research Delivery Method and Exogenous Protein Research
The research described above — including the human clinical trials — used gene therapy delivery via adeno-associated virus (AAV) vectors to deliver the FS344 transgene directly into muscle tissue, resulting in sustained local and circulating expression of FS315 protein. This is fundamentally different from exogenous recombinant follistatin protein injection.
The pharmacokinetic profile of exogenous recombinant follistatin protein administered by subcutaneous or intramuscular injection is not established in published peer-reviewed human dose-response studies. The half-life of circulating follistatin protein in plasma is short, and exogenous protein would be subject to rapid proteolytic degradation, clearance, and diffusion away from the injection site — all of which differ substantially from the sustained high-level local expression produced by AAV gene delivery over months to years.
Published peer-reviewed dose-response data for exogenous recombinant follistatin 344 protein injection in humans does not exist in the current literature. The dosing parameters used in research and clinical settings for protein injection are empirically derived from animal research extrapolation, gene therapy dosing contexts, and community experience rather than controlled human pharmacokinetic or dose-response trials. Researchers studying exogenous follistatin protein should be aware that the robust efficacy data from AAV gene therapy trials does not automatically translate to the exogenous protein injection context, which involves a fundamentally different delivery pharmacology.
Additional Research Contexts
Sarcopenia and muscle wasting: The myostatin pathway is an active area of research for age-related muscle loss (sarcopenia) and cancer or disease-related muscle wasting (cachexia). Selective ActRIIB antibodies such as bimagrumab have reached Phase 3 clinical trials for sIBM and early trials for obesity-associated muscle loss — providing adjacent human evidence that myostatin pathway inhibition is a viable clinical strategy, though these are not follistatin specifically.
Duchenne muscular dystrophy: Phase 1/IIa trials of AAV1.CMV.FS344 in DMD patients were initiated following the BMD trial results, with a revised protocol extending delivery to multiple muscle groups.
Pompe disease adjuvant therapy: Preclinical studies in Pompe disease mice demonstrated that follistatin could be used as adjuvant therapy to alpha-glucosidase replacement, suggesting potential for combination approaches in glycogen storage muscle diseases.
Insulin sensitivity and metabolic research: The TGF-beta and myostatin pathways have been linked to insulin resistance in sarcopenic and metabolically compromised states, positioning follistatin pathway research as relevant to metabolic as well as neuromuscular disease contexts.
Current Research Status
Follistatin 344 is not approved by the FDA for any indication as a recombinant protein or gene therapy product. It is classified as a prohibited substance by WADA under both S2 (peptide hormones, growth factors, and related substances) and S4.3 (gene doping) categories.
Gene therapy using AAV1.CMV.FS344 has progressed through Phase 1/2a human trials in Becker muscular dystrophy with an encouraging safety profile and mixed but partly positive functional outcomes. Trials in sporadic inclusion body myositis and Duchenne muscular dystrophy were initiated based on these results. No Phase 3 trials of FS344 gene therapy have been published as of the knowledge cutoff of this document.
The following remain unestablished in the published literature:
Human pharmacokinetic and dose-response data for exogenous recombinant follistatin 344 protein administration.
Long-term safety profile of chronic myostatin and activin suppression in humans.
Effects on reproductive endocrinology with sustained activin inhibition from exogenous FS315.
Effects on bone metabolism, adipogenesis, and neural development through the BMP signaling pathways also antagonized by follistatin.
Phase 3 efficacy and safety trial results for any follistatin gene therapy indication.
Reconstitution Note
Follistatin 344 is a large glycoprotein. It is sensitive to mechanical stress and should be reconstituted gently without vigorous shaking or vortexing, which can cause protein aggregation and loss of biological activity. Bacteriostatic water is the standard reconstitution solvent. After reconstitution use within the timeframe specified in the product datasheet. Always confirm the recommended solvent, concentration, and handling protocol against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: As a large glycoprotein, follistatin 344 is more sensitive to handling conditions than smaller synthetic peptides. Gentle handling during reconstitution and storage is particularly important. Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard protein handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Follistatin 344 product page: https://roguecompounds.com/product/follistatin-344/